Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice sevabertinib (Hyrnuo) Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PHAR.764

    Sevabertinib (Hyrnuo) coverage

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.764 alerts

    Get alerted when Policy CP.PHAR.764 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines clinical coverage, prior authorization criteria, and administration/dosing guidance for sevabertinib (Hyrnuo) for qualifying members across commercial, HIM, and Medicaid lines of business.

    Policy Summary
    PayerQualChoice
    PolicySevabertinib (Hyrnuo) coverage
    Policy CodePolicy CP.PHAR.764
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that the member meets all approval criteria for initial and continued therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsapproval duration
    20 mg BIDrecommended dosing
    40 mg/daymax daily dose
    10 mgtablet strength
    C9399, J8999HCPCS codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy — Non-Small Cell Lung Cancer

    Covered when ALL of the following are met:

    NSCLC initial approval criteria: 1. Diagnosis of recurrent, advanced (including locally advanced), or metastatic non-small cell lung cancer (NSCLC); 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Prescribed as single agent; 5. Disease has activating HER2 (ERBB2) mutations; 6. Failure of a prior systemic therapy (see Appendix B for examples); 7. Member has not previously experienced disease progression while on Hernexeos (zongertinib); 8. For Hyrnuo requests, member must use sevabertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 9. Dose of Hyrnuo is ≥ 10 mg per day; 10. Request meets one of the following: (a) dose does not exceed 40 mg (4 tablets) per day; or (b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Prescribed regimen must be FDA-approved or recommended by NCCN.

    Approval duration: 12 months

    Continuation Therapy — Non-Small Cell Lung Cancer

    Covered when ALL of the following are met:

    NSCLC continuation criteria: 1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Hyrnuo for a covered indication and has received this medication for at least 30 days; 2. Member is responding positively to therapy; 3. For Hyrnuo requests, member must use sevabertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 4. Dose of Hyrnuo is ≥ 10 mg per day; 5. If request is for a dose increase, request meets one of the following: (a) new dose does not exceed 40 mg (4 tablets) per day; or (b) new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Prescribed regimen must be FDA-approved or recommended by NCCN.

    Approval duration: 12 months

    Requests for indications that are not FDA‑approved and are not specifically addressed in this policy will not be authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (see CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or unless coverage is supported by the member’s evidence of coverage. Prior authorization is required and approval hinges on submission of clinical documentation demonstrating the request meets all applicable criteria for initial or continued therapy.

    Coverage determinations under this policy are subject to the terms, conditions, exclusions, and limitations of the member’s coverage documents (for example, evidence of coverage, certificate of coverage, policy or contract of insurance) and to applicable state and federal requirements and Health Plan administrative policies and procedures. Providers must follow those coverage documents and any applicable Health Plan administrative policies when requesting authorization; conflicts with state Medicaid provisions will be governed by the applicable state Medicaid manual.

    Uses that are non‑FDA approved and not addressed by this policy are considered not authorized and may be denied unless the request includes sufficient documentation per the referenced off‑label use policies or the member’s evidence of coverage that justifies approval.

    Coding and Dosing Limits

    HCPCS Codes (informational)HCPCS
    C9399Unclassified drugs or biologicals
    J8999Prescription drug, oral, chemotherapeutic, nos
    Maximum daily dose
    Maximum daily dose≤ 40 mg/day
    Recommended NSCLC regimen20 mg PO BID (total 40 mg/day)
    Tablet strength referenced10 mg tablet
    Sevabertinib (Hyrnuo) quantity limit
    Sevabertinib (Hyrnuo) daily quantity limit≤ 40 mg per day
    Per-dose regimen noted20 mg PO BID recommended for NSCLC
    Approval constraintDose must be ≥ 10 mg/day and not exceed 40 mg/day unless supported by guidelines or literature

    Provider Actions & Authorization

    Prior Authorization

    Prior authorization required with supporting documentation

    Prior authorization is required for both initial and continued therapy. Providers must submit documentation that all approval criteria are met; coding implications reference HCPCS codes C9399 and J8999 for billing.

    • Prior authorization required for initial and continuation requests.
    • Include documentation demonstrating each approval criterion is met.
    • Billing/coding references: C9399, J8999.
    Prior Authorization

    Policy serves as medical necessity guide for prior authorization

    This clinical policy is intended to serve as a guide to medical necessity to assist in making coverage decisions and administering benefits; prior authorization requests must follow the Health Plan's established processes and the terms of the member's coverage documents.

    • Policy guides medical necessity determinations used in authorization decisions.

    Initial Therapy — Hyrnuo

    Initial Therapy — Hyrnuo

    Initial approval criteria for NSCLC

    Initial therapy nodes: 1. Diagnosis: recurrent, advanced (including locally advanced), or metastatic nonsmall cell lung cancer (NSCLC). 2. Prescriber: prescribed by or in consultation with an oncologist. 3. Age: patient is ≥ 18 years. 4. Regimen: prescribed as a single agent. 5. Biomarker: tumor has activating HER2 (ERBB2) mutations. 6. Prior therapy: documented failure of a prior systemic therapy (see Appendix B for examples). 7. Prior drug history: member has not previously experienced disease progression while on Hernexeos (zongertinib). 8. Product availability: for Hyrnuo requests, member must use sevabertinib, if available, unless contraindicated or clinically significant adverse effects are experienced. 9. Minimum dose: dose of Hyrnuo is ≥ 10 mg per day. 10. Dose limits: request meets one of the following: (a) dose does not exceed 40 mg (4 tablets) per day; or (b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Prescribed regimen must be FDA-approved or recommended by NCCN.

    Approval duration: 12 months

    Continuation Therapy — Hyrnuo

    Continuation Therapy — Hyrnuo

    Continuation therapy coverage conditions

    Continuation therapy nodes: 1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Hyrnuo for a covered indication and has received this medication for at least 30 days; 2. Member is responding positively to therapy; 3. For Hyrnuo requests, member must use sevabertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 4. Dose of Hyrnuo is ≥ 10 mg per day; 5. If request is for a dose increase, request meets one of the following: (a) new dose does not exceed 40 mg (4 tablets) per day; or (b) new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Prescribed regimen must be FDA-approved or recommended by NCCN.

    Approval duration: 12 months

    Step Therapy Requirements

    StepRequirementDetails
    1Prior systemic therapy requiredFailure of a prior systemic therapy is required for initial approval; see Appendix B for examples of prior systemic therapies (therapeutic alternatives).

    Site of Care

    Note

    Site of care: oral tablet — no site restriction

    Sevabertinib (Hyrnuo) is an oral tablet and the policy does not restrict site of care; dispensing for home use is allowed per the policy.

    • Site of care is not restricted in policy text.

    Definitions

    NSCLC
    TermNon-small cell lung cancer (NSCLC)
    DefinitionA type of lung cancer referenced as 'non-small cell lung cancer' (NSCLC) in this policy
    Indication contextSevabertinib is indicated for adult patients with locally advanced or metastatic nonsquamous NSCLC with HER2 activating mutations
    HER2 (ERBB2) activating mutations
    TermHER2 (ERBB2) activating mutations
    DefinitionTumor mutations in the HER2 (ERBB2) tyrosine kinase domain as detected by an FDA-approved test
    Relevance

    Background

    Sevabertinib (Hyrnuo) is an oral tyrosine kinase inhibitor developed for treatment of adult patients with locally advanced or metastatic nonsquamous non‑small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) tyrosine kinase domain mutations. The agent received accelerated approval for this indication in patients who have received prior systemic therapy; continued approval may depend on verification of clinical benefit from confirmatory trials. Sevabertinib is administered orally and dosing guidance in this policy reflects the approved regimen and quantity limits.

    Policy Summary
    PayerQualChoice
    PolicySevabertinib (Hyrnuo) coverage
    Policy CodePolicy CP.PHAR.764
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that the member meets all approval criteria for initial and continued therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing LimitsProvider Actions & AuthorizationInitial Therapy — HyrnuoContinuation Therapy — HyrnuoStep Therapy RequirementsSite of CareDefinitionsBackground
  1. Prior authorization requirements follow Health Plan processes and member coverage terms.
  2. Step Therapy

    Therapeutic alternatives (Appendix B) may be required

    Therapeutic alternatives are listed in Appendix B and may be required or considered prior to approval depending on formulary status and plan requirements.

    • See Appendix B for preferred alternative therapies and dosing examples.
    • Alternatives may require their own prior authorization if not formulary.
    Step Therapy

    No formal step therapy specified; prior systemic therapy required

    No specific step therapy sequence is specified in this policy text; however, initial approval requires failure of a prior systemic therapy as described in the criteria (see Appendix B for examples).

    • Policy does not define a formal step therapy algorithm.
    • Initial approval criterion requires prior systemic therapy failure.
    Documentation Required

    Required documentation to support authorization

    Providers must submit clinical documentation such as office chart notes, laboratory results, and other pertinent clinical information to demonstrate the member meets all approval criteria.

    • Office notes documenting diagnosis and oncologist involvement.
    • Laboratory or pathology reports confirming HER2 (ERBB2) activating mutation.
    • Records showing prior systemic therapy and treatment response or progression history.
    Documentation Required

    Adhere to member coverage documents and Health Plan procedures

    Providers must follow the member's coverage documents and applicable Health Plan administrative policies and procedures when requesting coverage; coverage decisions are administered in accordance with those documents.

    • Adhere to evidence of coverage, certificate of coverage, policy, and contract of insurance terms.
    • Follow any applicable Health Plan-level administrative policies and procedures when submitting requests.
    Denial Risk

    Off‑label indications may be denied without supporting documentation

    Requests for non‑FDA approved (off‑label) indications that are not addressed in this policy may be denied unless sufficient documentation is provided in accordance with the Health Plan's off‑label use policies or the member's evidence of coverage.

    • Off‑label requests must include evidence of efficacy and safety per off‑label use policies (see CP.CPA.09, HIM.PA.154, CP.PMN.53).
    • Non‑FDA uses not supported by the policy or off‑label criteria are considered not authorized and may be denied.
    Note

    Coverage subject to member coverage terms and regulatory requirements

    Coverage decisions are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable state and federal requirements; conflicts with state Medicaid provisions take precedence and may affect authorization.

    • Decisions are governed by the member's evidence of coverage and plan contract.
    • Applicable state and federal requirements and Health Plan administrative policies apply and may override this policy where required.
    Required for sevabertinib indication in NSCLC; disease must have activating HER2 (ERBB2) mutations
    Health Plan
    TermHealth Plan
    DefinitionA health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any affiliate
    Policy roleUses this clinical policy as a guide to medical necessity for coverage decisions and benefit administration